How AI Will Accelerate Breakthroughs in Biotechnology with Benchling CEO Sajith Wickramasekara

What It Covers

Benchling CEO Sajith Wickramasekara explains how AI agents can compress drug development timelines from seven to ten years down to two to three years by automating experiments, unlocking institutional memory, and improving molecular design decisions.

Key Questions Answered

• •Drug Development Cost Structure: Bringing a medicine to market requires over $2 billion and ten years, with most failures occurring late in clinical trials after hundreds of millions spent, making it harder than sending people to space currently.
• •Chinese Biotech Competition: Chinese biotech companies now develop molecules and reach clinical trials significantly faster and cheaper than American biotechs, leading top 30 pharma companies like Johnson & Johnson to increasingly purchase molecules from China instead of US startups.
• •AI Agent Implementation: Benchling's deep research agent helped one customer avoid an eight month, expensive mouse study by discovering in minutes that identical experiments existed in old lab notebooks from an acquired company, demonstrating how AI unlocks trapped institutional knowledge.
• •Scientific Data Inefficiency: Biotech operates with bespoke, artisanal workflows because companies focus on surviving six to seven years until acquisition rather than building scalable systems, creating massive opportunity for AI to standardize and accelerate the 9,999 steps after initial molecule discovery.